Oncogenex Pharma (OGXI) 0.89 $OGXI Rexahn's Drugs Deal a

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncogenex Pharma (OGXI) 0.89 $OGXI

Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.27 (+0.01), OGXI: 0.89 (unch), AMGN: 174.14 (+2.11), LLY: 83.45 (+0.56), BMY: 75.84 (+1.03), MNTA: 11.43 (+0.17), CELG: 114.09 (+1.90), EXEL: 9.25 (+0.07)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016
CNW Group - Thu May 12, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter 2016 financial results and provided a summary of anticipated milestones.
OGXI: 0.89 (unch)

OncoGenex to Report First Quarter 2016 Financial Results on May 12, 2016
PR Newswire - Thu Apr 28, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its first quarter 2016 financial results on Thursday, May 12, 2016. Company management will host a conference call and live webcast at 4:30 p.m. Eastern Time to provide an overview of financial results, clinical development programs and a general corporate update.
OGXI: 0.89 (unch)

Analyst Review and Estimates; OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)
ACCESSWIRE - Tue Apr 26, 1:05PM CDT
BOTHELL, WA and VANCOUVER, BC / ACCESSWIRE / April 26, 2016 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5). There are a several analyst covering OGXI's securities. The focus of the following report is several analyst rating and the companies drug pipeline and progress.
OGXI: 0.89 (unch)

Trending Stocks: Four of Wall Street's Most Active Equities on April 26, 2016
ACCESSWIRE - Tue Apr 26, 11:12AM CDT
MIAMI, FL / ACCESSWIRE / April 26, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. OGXI, LPTN, UPL, and CPLP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OGXI: 0.89 (unch), UPL: 0.31 (unch), CPLP: 3.65 (-0.12), LPTN: 1.93 (-0.02)

These 4 Small Cap Stocks Are Having Big Volume Days Today
ACCESSWIRE - Tue Apr 26, 9:38AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SEED, OGXI, NVIV and TCS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
NVIV: 6.45 (-0.03), OGXI: 0.89 (unch), SEED: 2.15 (-0.02), TCS: 5.44 (-0.09)

OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 05, 3:02PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that John Bencich, Chief Financial Officer at OncoGenex, will present at the 15th Annual Needham Healthcare Conference on April 13, 2016 at the Westin Grand Central Hotel in New York City.
OGXI: 0.89 (unch)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015
PR Newswire - Wed Mar 09, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced year end 2015 financial results and provided a summary of anticipated milestones.
OGXI: 0.89 (unch)

OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities
CNW Group - Thu Feb 04, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it is implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%. The Company expects cost savings associated with the reduction of employees and consultants, together with the elimination of certain planned expenditures not required for the completion of ongoing trials, will extend cash runway into the third quarter of 2017.
OGXI: 0.89 (unch)

OncoGenex Cancer Drug Fails to Show PFS in Phase II Trial
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 11:50AM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen failed to achieve the primary endpoint in an ongoing mid-stage study for NSCLC.
IMDZ: 7.55 (-0.12), EARS: 4.16 (+0.15), OGXI: 0.89 (unch), CORT: 5.89 (+0.09)

OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer
PR Newswire - Wed Jan 20, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from the Phase 2 Spruce(TM) trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.
OGXI: 0.89 (unch)

Market Influences That Drive Equities Forward - New Research on Lionbridge Technologies, Ceres, Tejon Ranch and OncoGenex Pharmaceuticals
ACCESSWIRE - Fri Dec 18, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lionbridge Technologies Inc. (NASDAQ: LIOX), Ceres Inc. (NASDAQ: CERE), Tejon Ranch Co. (NYSE: TRC) and OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
TRC: 26.50 (+0.23), OGXI: 0.89 (unch), CERE: 0.40 (unch), LIOX: 4.52 (+0.01)

OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis
PR Newswire - Wed Dec 09, 6:00AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the independent Data Safety Monitoring Board (DSMB) at Dana-Farber/Harvard Cancer Center has recommended that the Phase 2 Borealis-2(TM) trial continue as planned after completing the pre-specified futility analysis.
OGXI: 0.89 (unch)

OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses
PR Newswire - Tue Dec 01, 3:01PM CST
Final Results Expected in Second Half of 2016
OGXI: 0.89 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 360

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 251

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 41

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 120

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 95

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 229

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 79

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

Marqeta Class Action Lawsuit: Investor Rights Alert

Updated Category News Views 115

Investors Take Action: Marqeta, Inc. Securities Lawsuit In an important update for shareholders of Marqeta, Inc. (NASDAQ: MQ), it has been brought to attention by Kahn Swick & Foti, LLC that investors who have incurred losses exceeding $100,000 have until a specific deadline to file lead plaintiff applications in a key class action lawsuit. Understanding the Class Action...

Continue Reading
Emerging Strategies for the Chronic Refractory Cough Market

Updated Category News Views 266

Chronic Refractory Cough Market Overview The chronic refractory cough market is emerging as a significant opportunity for pharmaceutical companies. As analyzed, the market size is poised for considerable growth due to various factors, including rising disease prevalence and a corresponding increase in approved product availability. Notably, several innovative therapies...

Continue Reading
Hydreight Technologies: A Rising Star in Healthcare Services

Updated Category News Views 185

Hydreight Technologies Achieves Major Recognition In the fast-paced world of technology and healthcare, Hydreight Technologies Inc. has made an impressive mark, securing the spot of No. 77 on a prestigious list of the fastest-growing companies in North America. This ranking, part of the 2025 Deloitte Technology Fast 500™, positions Hydreight among elite innovators and...

Continue Reading
Empowering Communities: PHFA's $75 Million Housing RFP Launch

Updated Category News Views 90

Introducing the New PHARE Funding Opportunities for Housing The Pennsylvania Housing Finance Agency (PHFA) is excited to announce a new funding opportunity that aims to improve housing availability and affordability across the state. This initiative encourages organizations to submit proposals for projects designed to address urgent housing challenges in their...

Continue Reading
Investigating Investor Claims Against Polestar Automotive

Updated Category News Views 114

Investigation of Investor Claims Against Polestar Automotive Faruqi & Faruqi, LLP, a prominent national securities law firm, is initiating an investigation into potential claims for investors of Polestar Automotive Holding UK PLC. If you've experienced financial losses linked to Polestar, now is the time to explore your options and safeguard your rights. Understanding...

Continue Reading